SM08502-Mediated β-Catenin Repression Synergizes with Olaparib to Inhibit Tumor Progression
PARPi resistance is a major clinical challenge. Overcoming PARPi resistance will provide patients with therapeutic options. The study shows, in the context of resistant disease, the potential of targeting CDC-like kinase/dual-specificity tyrosine phosphorylation-regulated kinase alone and in combination with PARP inhibitors.
Authors
- Tomomi M. Yamamoto (ORCID: https://orcid.org/0000-0002-6666-5406)
- Benjamin G. Bitler (ORCID: https://orcid.org/0000-0002-5809-5271)
- Alexandra Young (ORCID: https://orcid.org/0009-0005-8709-439X)
- Thomas Danhorn (ORCID: https://orcid.org/0000-0002-3861-8602)
- Kimberly Rae Jordan (ORCID: https://orcid.org/0000-0001-8380-7157)
- Edward B. Chuong (ORCID: https://orcid.org/0000-0002-5392-937X)
- Bradley R. Corr (ORCID: https://orcid.org/0000-0002-6608-2585)
- Linda Wick (ORCID: https://orcid.org/0009-0008-3479-8053)
- Carine Bossard (ORCID: https://orcid.org/0009-0005-2508-7282)
- Lily L. Nguyen (ORCID: https://orcid.org/0000-0003-4425-2536)
- Lisa Barroilhet (ORCID: https://orcid.org/0000-0001-9315-2414)
- Elizabeth R. Woodruff (ORCID: https://orcid.org/0000-0003-0237-7453)
- Sandra Oršulić (ORCID: https://orcid.org/0000-0001-5119-8721)
- S. Kusumoto (ORCID: https://orcid.org/0000-0002-4551-6719)
Institutions
- University of Wisconsin–Madison (US)
- University of California, Los Angeles (US)
- University of Colorado Boulder (US)
- AnaBios (United States) (US)
- University of Colorado Cancer Center (US)
- Caris Life Sciences (United States) (US)
- VA Greater Los Angeles Healthcare System (US)
- University of Colorado Anschutz Medical Campus (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1158/2767-9764.crc-25-0267
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00